Founder and CEO at LockBody Therapeutics, a Centessa company @ LockBody, a Centessa company (April 2017 - March 2023)
Scientific Advisory Board Member @ (July 2020 - November 2022)
Senior Director @ (April 2015 - January 2016)
Director @ (November 2011 - April 2015)
Principal Scientist @ (May 2006 - September 2009)
Senior Post-Doctoral Researcher @ (January 2004 - April 2006)
Post-Doctoral Researcher @ NIH CBER-FDA (January 2001 - January 2004)
William Finlay Education
Glasgow Caledonian University
PhD (Microbiology and Biochemistry)
1993-2001
Regent House Grammar School
William Finlay Skills
Antibodies
Biochemistry
Biomarkers
Biopharmaceuticals
Biotechnology
Cell
Cell Biology
Cell Culture
Clinical Development
Drug Development
Drug Discovery
Immunology
Life Sciences
Lifesciences
Molecular Biology
Monoclonal Antibodies
Phage Display
Presentation Skills
Protein Chemistry
Protein Engineering
Ribosome Display
Technology Transfer
William Finlay Summary
William Finlay, based in United Kingdom, is currently a Co-Founder at Granular Therapeutics Ltd. William Finlay brings experience from previous roles at Ottimo Pharma, mAbs Journal, Centessa Pharmaceuticals and ULTRAHUMAN LIMITED. William Finlay holds a 1993 - 2001 PhD in Microbiology and Biochemistry @ Glasgow Caledonian University. With a robust skill set that includes Antibodies, Biochemistry, Biomarkers, Biopharmaceuticals, Biotechnology and more. William Finlay has 1 emails on RocketReach.
Looking for a different William Finlay?
Find contact details for 700 million professionals.